Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6115460 | Diagnostic Microbiology and Infectious Disease | 2015 | 8 Pages |
Abstract
This study evaluated the impact of leprosy multidrug therapy (MDT) on cell-mediated immunity (CMI) and antibody responses at diagnosis in untreated paucibacillary (PB) (n = 15) and multibacillary (MB) patients (n = 15) using a panel of Mycobacterium leprae recombinant antigens (rMLs) (CMI: 46f, ML0276, ML2055, leprosy IDRI diagnostic 1 [LID-1], and ML2629, as negative control; serology: LID-1, 46f, 92f, and 33f, as negative control, and phenolic glycolipid I [PGL-I]) and at 2 time points after MDT (PB: 8-20 months; MB: 4-22 months). At diagnosis, PB patients produced interferon gamma (IFNγ), and MB patients exhibited low/absent response. Shortly after MDT, IFNγ production in PB patients declined except for LID-1; MB patients produced IFNγ to LID-1. Almost 2 years after MDT, IFNγ levels declined in PB and MB patients. Most untreated PB patients were seronegative to PGL-I and rML, remaining so after MDT. Most untreated MB patients were seropositive to all antigens, and IgG to rMLs declined after MDT. Reduction in antigen-specific CMI in PB and in antibody response in MB patients may help monitor MDT effectiveness.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Aline Araújo Freitas, Regiane Morillas Oliveira, Emerith Mayra Hungria, Ludimila Paula Vaz Cardoso, Ana Lúcia Osório Maroccolo Sousa, MaurÃcio Barcelos Costa, Steven G. Reed, Malcolm S. Duthie, Mariane Martins Araújo Stefani,